|
Prevention and Therapeutic Targets |
 |
 |
|
VacciGuard's vaccine technology has broad potential for both the prevention of multiple infectious diseases, where there is yet no effective vaccine solution, and for the treatment of devastating diseases, such as cancer and Alzheimer's disease.
At present, the Company focuses its efforts on two prevention targets and one therapeutic target:
- Vaccine for the West Nile Virus.
- Vaccine for the treatment of Lung Cancer.
Project Name
|
VG-WNV |
VG-LC |
| Pathogen/Indication |
West Nile Virus |
Lung Cancer |
Death/year
(US 2007) |
115 D/1187 encephalitis |
160,390 |
| Market Size |
$400M (est.) |
$3.7B (Non small cell) |
| Current Status |
Supporting results in animal models (5 repetitions) |
Successfully repeated animal experiments |
|
|
<< Start < Prev 1 2 3 4 5 6 7 Next > End >>
|
Vaccine Pipeline